Compare Chevron Corp (CVX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Mesoblast Limited — how do they compare? Chevron Corp trades at $212.35 (market cap $414.98B), while Mesoblast Limited trades at $14.33 (market cap $1.75B). The key difference: Chevron Corp is far larger — about 237.1× Mesoblast Limited's market cap, and Chevron Corp pays a 3.37% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and Mesoblast Limited for 14 Days on average.
| CVX | MESO | |
|---|---|---|
Market Cap | $414.98B | $1.75B |
Volume | 7,575,112 | 239,027 |
Sector | Energy | Health |
52-Week High | $217.73 | $20.96 |
52-Week Low | $146.72 | $13.19 |
Typical Hold Time | 101 Days | 14 Days |
Enterprise Value | $443.52B | $1.83B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $205.19, down 1.17% on the day, with a neutral technical signal and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. Revenue declined to $184.43B in 2025, but a rebound to $208.7B is projected for 2026. Analyst consensus is a Buy with a $208.31 price target, and the company maintains a strong balance sheet with $6.79B in cash.
CVX presents a mixed outlook; earnings beats and a favorable analyst consensus support upside, but declining revenue and net income margins pose risks. High oil prices and strategic investments, like the $13.8B Argentina project, offer growth potential, yet geopolitical tensions and volatile energy markets remain headwinds for shareholders.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
